Malaria Research Program, Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, Maryland, USA.
University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
J Infect Dis. 2021 Sep 17;224(6):1077-1085. doi: 10.1093/infdis/jiab055.
Newly emerged mutations within the Plasmodium falciparum chloroquine resistance transporter (PfCRT) can confer piperaquine resistance in the absence of amplified plasmepsin II (pfpm2). In this study, we estimated the prevalence of co-circulating piperaquine resistance mutations in P. falciparum isolates collected in northern Cambodia from 2009 to 2017.
The sequence of pfcrt was determined for 410 P. falciparum isolates using PacBio amplicon sequencing or whole genome sequencing. Quantitative polymerase chain reaction was used to estimate pfpm2 and pfmdr1 copy number.
Newly emerged PfCRT mutations increased in prevalence after the change to dihydroartemisinin-piperaquine in 2010, with >98% of parasites harboring these mutations by 2017. After 2014, the prevalence of PfCRT F145I declined, being outcompeted by parasites with less resistant, but more fit PfCRT alleles. After the change to artesunate-mefloquine, the prevalence of parasites with amplified pfpm2 decreased, with nearly half of piperaquine-resistant PfCRT mutants having single-copy pfpm2.
The large proportion of PfCRT mutants that lack pfpm2 amplification emphasizes the importance of including PfCRT mutations as part of molecular surveillance for piperaquine resistance in this region. Likewise, it is critical to monitor for amplified pfmdr1 in these PfCRT mutants, as increased mefloquine pressure could lead to mutants resistant to both drugs.
疟原虫氯喹耐药转运蛋白(PfCRT)中出现的新突变可在没有扩增的质体蛋白酶 II(pfpm2)的情况下赋予哌喹耐药性。在这项研究中,我们估计了 2009 年至 2017 年在柬埔寨北部采集的疟原虫分离株中共同循环的哌喹耐药突变的流行率。
使用 PacBio 扩增子测序或全基因组测序确定了 410 株疟原虫PfCRT 的序列。定量聚合酶链反应用于估计 pfpm2 和 pfmdr1 拷贝数。
2010 年改用二氢青蒿素-哌喹后,新出现的 PfCRT 突变的流行率增加,到 2017 年,超过 98%的寄生虫携带这些突变。2014 年后,PfCRT F145I 的流行率下降,被耐药性较低但更适合 PfCRT 等位基因的寄生虫所取代。改用青蒿琥酯-甲氟喹后,携带扩增 pfpm2 的寄生虫的流行率下降,近一半的哌喹耐药 PfCRT 突变体只有单拷贝 pfpm2。
缺乏 pfpm2 扩增的 PfCRT 突变体的比例很大,这强调了在该地区将 PfCRT 突变作为哌喹耐药性分子监测的一部分的重要性。同样,监测这些 PfCRT 突变体中扩增的 pfmdr1 也至关重要,因为增加的甲氟喹压力可能导致对这两种药物都耐药的突变体。